



The compilation of presentations is for educational purposes only. Copies of presentations obtained through the hyperlinks are live the day of the presentation and **per the meeting's guidelines, the hyperlink links to either the Pfizer Conference Publications Portal or the conference website for obtaining the presentation. Copies of presentations obtained through the hyperlinks are for personal use only and may not be reproduced without permission from the conference and the author of those presentations.** All copyrights protected by law. Solely for non-commercial use.

## Pfizer-Sponsored Poster Presentations

---

### Poster Session: Analyses Using Clinical and Genomic Databases

Sunday, April 16

1:30 PM – 5:00 PM (ET)

**Talazoparib**

**Presentation 930**

Treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer harboring DDR mutations

Solit D

[View Presentation](#)

---

### Poster Session: Phase II and Phase III Clinical Trials in Progress

Monday, April 17

9:00 AM – 12:30 PM (ET)

**Encorafenib and Binimetinib**

**Presentation CT069**

Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Schadendorf D

[View Presentation](#)

---

### Poster Session: Spatial Profiling, Tumor Classification, and Response Assessment

Tuesday, April 18

9:00 AM – 12:30 PM (ET)

**Presentation 4543**

Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction

Karam J

[View Presentation](#)